A phase I study of CCI-779 [temsirolimus] in combination with imatinib mesylate in chronic myelogenous leukemia
Latest Information Update: 03 Nov 2021
Price :
$35 *
At a glance
- Drugs Imatinib (Primary) ; Temsirolimus (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions
- 11 Jan 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 27 Oct 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Aug 2010 New source identified and integrated (Moores UCSD Cancer Center).